Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical firm dedicated to creating immune-modulating therapies, specifically targeting immuno-oncology and fibrotic conditions. The company's pipeline includes several key candidates: Lenabasum, an oral compound currently in Phase II trials, works by selectively engaging cannabinoid receptor type 2 (CB2) to address systemic lupus erythematosus. Corbus is also advancing CRB-601, an anti-integrin monoclonal antibody designed to combat cancer and fibrosis by inhibiting transforming growth factor ß (TGFß) activation.